3,137 Shares in Insulet Corporation $PODD Bought by Marshall Financial Group LLC

Key Points

• Marshall Financial Group LLC acquired a new stake in Insulet Corporation, purchasing 3,137 shares valued at approximately $943,000 in the second quarter.
• Insulet reported earnings of $1.17 per share, surpassing estimates, with quarterly revenue reaching $649.10 million, a 32.9% increase year-over-year.
• Multiple brokerages have upgraded Insulet's rating, with a consensus rating of "Moderate Buy" and a target price of $343.06 per share.

Marshall Financial Group LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,137 shares of the medical instruments supplier's stock, valued at approximately $943,000.

A number of other hedge funds have also recently added to or reduced their stakes in PODD. Janus Henderson Group PLC boosted its stake in shares of Insulet by 7.0% in the 4th quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier's stock valued at $2,049,000 after purchasing an additional 511 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Insulet by 12.3% in the 4th quarter. ProShare Advisors LLC now owns 10,614 shares of the medical instruments supplier's stock valued at $2,771,000 after purchasing an additional 1,159 shares during the last quarter. Toronto Dominion Bank boosted its stake in shares of Insulet by 55.2% in the 4th quarter. Toronto Dominion Bank now owns 36,486 shares of the medical instruments supplier's stock valued at $9,526,000 after purchasing an additional 12,984 shares during the last quarter. Tidal Investments LLC boosted its stake in shares of Insulet by 9.8% in the 4th quarter. Tidal Investments LLC now owns 10,283 shares of the medical instruments supplier's stock valued at $2,685,000 after purchasing an additional 918 shares during the last quarter. Finally, Cornerstone Advisory LLC bought a new position in shares of Insulet in the 4th quarter valued at about $238,000.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Stock Performance

PODD stock traded up $2.98 during midday trading on Monday, reaching $333.82. 122,581 shares of the company were exchanged, compared to its average volume of 747,033. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business has a 50-day moving average price of $315.14 and a two-hundred day moving average price of $294.51. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The firm has a market capitalization of $23.50 billion, a price-to-earnings ratio of 101.33, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the topic of several recent research reports. Barclays raised their target price on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Wells Fargo & Company lifted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Finally, Raymond James Financial restated an "outperform" rating and set a $360.00 target price (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $343.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.